Global C-Reactive Protein Testing Market to reach USD 1.85 billion by 2027. Global C-Reactive Protein Testing Market is valued approximately 1.67 USD billion in 2020 and is anticipated to grow with a healthy CAGR of 1.5 % over the forecast period 2021-2027.
C-Reactive Protein or CRP is a protein synthesized by liver. CRP testing is often done to detect inflammation in the body resulting from a serious infection after surgery, injury, or chronic diseases such as cancer, and cardiovascular ailments. A high CRP level in blood indicates that a chronic disease or an injury is severe. Rise in cardiovascular diseases and death resulting from it is a major driver of C-Reactive Protein Testing market. As per World Heart Federation, Coronary Heart Disease causes death of 3.8 million men and 3.4 million women every year. CRP is a good method of diagnosing a heart disease in early stages and keeping a track of its severity.
Another driving factor for the market is the sheer volume of tests required per every patient. With CRP tests conducted weekly or every couple few days in patients of arthritis, cardiovascular diseases, bowel disorders, the demand for CRP testing stays high.
However, lack of public awareness towards the benefits of CRP testing can impede market growth during the forecast period 2021-27. Nevertheless, development of new techniques for C-Reactive Protein testing is likely to increase the market growth during the forecast period.

Regional analysis of Asia Pacific, North America, Europe, Latin America, and Rest of the World, shows that North America is the most significant player across the world in terms of market share owing to the advanced medical infrastructure, prevailing cardiovascular diseases resulting from unhealthy lifestyle, and presence of established players. At the same time, North America is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027. Factors such as rising research partnerships, increasing government investments in pharmaceuticals, and increasing geriatric population would create lucrative growth prospects for the C-Reactive Protein Testing Market across North America region.

Major market player included in this report are:
Abcam
Bio-techne (R&D Systems)
F. Hoffmann-La Roche AG
Randox Laboratories Ltd.
Merck & Co., Inc.
Thermo Fisher Scientific Inc.
Lifespan Biosciences, Inc.
Abaxis, Inc.
Quest Diagnostics
Siemens Healthineers

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Assay Type:
ELISA
Turbidimetric
Immunoturbidimetric
By End User:
Hospitals
Clinics
Diagnostics Labs
By Application:
Cardiovascular
Inflammatory Disease
Rheumatoid Arthritis
Cancer
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global C-Reactive Protein Testing Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors